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Human immunodeﬁciency virus (HIV)–
associated tuberculosis (TB) carries
a high mortality risk and accounts for
approximately 25% of global HIV/AIDS
deaths each year [1]. Case management
requires a combination of appropriate
antituberculosis treatment, antiretroviral
therapy (ART), and trimethoprim-
sulphamethoxazole prophylaxis against
other opportunistic infections [2]. ART
reduces mortality by 64%–95% in
patients with drug-susceptible TB [3],
and trimethoprim-sulphamethoxazole
prophylaxis halves mortality risk [4].
For patients with HIV-associated TB
involving the central nervous system
(CNS) or pericardium, adjunctive
treatment with corticosteroids is also
recommended [5].
Despite the clear beneﬁts of ART, the
optimal time to initiate ART during TB
treatment has remained unclear, since
this is associated with a complex series of
competing risks that may vary between
different settings and patient pop-
ulations [6, 7]. However, the cumulative
ﬁndings from observational studies and
more recent randomized controlled tri-
als indicate that delays in ART initiation
are associated with increased mortality
among patients with TB across a wide
spectrum of baseline CD41 cell counts
[6, 8–11]. With this growing evidence
base, the World Health Organization
(WHO) has revised the ART guidelines
for resource-limited settings on several
occasions between 2002 and 2010, rec-
ommending progressively earlier initia-
tion of ART during TB treatment [12].
The most recent revision of these
guidelines, published in 2010, recom-
mended that ART be given to all patients
with TB regardless of CD41 cell count,
should be started as soon as possible
after TB treatment is tolerated, and
should not be initiated later than after 8
weeks of TB treatment [12]. However,
these guidelines may be further reﬁned
as data emerge from additional trials
being conducted in different settings and
patient groups [6].
In this issue of Clinical Infectious
Diseases,T o ¨ro ¨k et al [13] present im-
portant ﬁndings from a well-conducted
randomized controlled trial in Vietnam
in which they investigated the optimum
timing of ART among patients with
TB meningitis. They studied a cohort of
253 patients who received local standard
of care and compared the outcomes of
patients randomized to start ART either
during the ﬁrst week of TB treatment or
after 2 months of TB treatment. The
primary end-point was mortality during
a 9-month follow-up period. The
double-blind placebo-controlled design
was robust and adequately powered, and
randomization was good. Case deﬁ-
nitions were appropriate, and with
careful microbiological investigation,
a majority of cases were conﬁrmed by
culture. However, the overall ﬁnding
was that there was no statistically sig-
niﬁcant difference in survival between
the 2 study arms. Moreover, this nega-
tive ﬁnding was observed in patients
across all TB meningitis severity grades.
So why was mortality not inﬂuenced
by the timing of ART? Even taking into
account the advanced immunodeﬁ-
ciency of these patients (median CD41
cell count, 41 cells/lL), it was never-
theless striking that 58% (146 of 253)
of the patients died during follow-up. It
is well recognized that patients in re-
source-limited settings with WHO stage
4 disease (AIDS) and/or CD41 cell
counts ,50 cells/lL have very high
mortality risk both before ART [14] and
during early ART [15], but mortality
risk rapidly decreases in direct
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covery [16]. However, in this study,
overall mortality risk (and risk stratiﬁed
by TB meningitis grade) was similar to
that reported in studies of HIV-associ-
ated TB meningitis conducted in the
same setting prior to the availability of
ART [17, 18]. This questions the extent
to which this patient group derived
beneﬁt from ART and, in fact, whether
they beneﬁtted at all.
Although causes of death were not
deﬁned, the overriding risk factor for
death was the TB meningitis severity
grade, which suggests that deaths may
well have been largely attributable to
TB meningitis rather than to other HIV-
associated co-pathologies. It was also
notable that 85 (58.2%) of the 146
deaths occurred within the ﬁrst month
of observation, which further suggests
that many of the patients had such
advanced disease at study entry that
they simply could not be salvaged. Use
of dexamethasone is an important ad-
junctive therapy in HIV-uninfected pa-
tients with TB meningitis in this setting
and has been shown, in a randomized
controlled trial, to improve survival by
30% [18]. However, no conclusive
beneﬁt was demonstrated among pa-
tients with HIV-associated TB menin-
gitis in the same study, which was
conducted in the pre-ART era [18]. No
trials involving corticosteroids have been
performed among patients receiving
ART, because the use of corticosteroids
is now regarded as standard of care [5].
The high proportion of patients with
advanced TB meningitis severity grades
was a key factor in the overall mortality
and may have been related to the
prolonged symptom duration (median
duration of symptoms, 21 days; inter-
quartile range, 10–30 days) prior to
study entry. Because the Hospital for
Tropical Diseases in Ho Chi Minh City
is a tertiary referral hospital that serves
a population of 38 million people in
southern Vietnam [17], referral delays
from peripheral hospitals may be
prolonged, and delays may be further
compounded by the difﬁculties inherent
in the diagnosis of TB meningitis. The
prolonged interval between symptom
onset and initiation of TB treatment
is likely to have contributed to poor
outcomes and must be reduced.
Four patients had multidrug-resistant
TB meningitis, which is strongly pre-
dictive of death [19]; no second-line
therapy was available for these patients.
Drug resistance proﬁles of other isolates
of Mycobacterium tuberculosis were not
reported, but .40% of isolates from
similar patients previously treated in this
setting had isoniazid mono-resistance
[17]. Although a previous study in this
setting found that isoniazid mono-
resistance was associated with slower
mycobacterial clearance from cerebro-
spinal ﬂuid (CSF) during treatment, this
was not associated with adverse clinical
outcomes [19]. However, in a study
from the United States of a cohort of
1614 patients with positive CSF culture
results, initial isoniazid resistance was
associated with an adjusted odds of
death of 2.1 (95% conﬁdence interval,
1.30–3.29) [20]. This strongly suggests
that the issue of isoniazid mono-
resistance and outcomes of treatment for
TB meningitis warrants further study.
Except for those with multidrug-
resistant TB, the mortality beneﬁts of
ART derived by patients with HIV-
associated TB are likely to primarily re-
sult from reductions in the risk of new
opportunistic infections, rather than
from enhanced clearance of mycobacte-
rial disease. However, the incidence
of new AIDS-deﬁning infections was
nevertheless very high, affecting 25% of
all patients in this study. The use of
high-dose adjunctive dexamethasone
may have contributed to this risk. It
was also notable that prophylaxis with
trimethoprim-sulphamethoxazole was
only started after 4 weeks from the
date of study inclusion, which was the
period with the highest mortality risk.
Some of the new AIDS-deﬁning events
(44 diagnoses of Pneumocystis jirovecii
pneumonia and 3 diagnoses of toxo-
plasmosis) might have been prevented
by earlier initiation of trimethoprim-
sulphamethoxazole prophylaxis.
A key concern with rapid ART initi-
ation is the higher risk of TB-associated
immune reconstitution disease (IRD)
[21], which is particularly severe when
associated with opportunistic infections
of the CNS [22]. Although IRD events
involving the CNS were not speciﬁcally
reported, all neurological events were
carefully documented and occurred with
similar frequency (in 40% of patients)
in each arm of the study. Furthermore,
the time to development of a neurologi-
cal event or death did not differ between
the arms. Thus, there was no evidence
that early ART initiation was associated
a higher frequency of CNS IRD events.
Use of high-dose dexamethasone is likely
to have ameliorated the frequency and
severity of this complication.
The study population largely com-
prised young, male intravenous drug
users, which is a population that is typ-
ically associated with considerable co-
morbidity. This may limit the extent to
which the ﬁndings of this study can be
generalized to other clinical populations.
Hepatitis C infection and hepatitis B
infection were detected among 51% and
14% of those patients who were tested,
respectively. These coinfections may
have contributed to the high frequency
of grade 3 and grade 4 hepatitis observed
in over one-ﬁfth of patients during
follow-up.
The main conclusion that this im-
portant study seems to suggest is that
HIV-associated TB meningitis in this
patient population has such a poor
prognosis that the timing of ART makes
no appreciable difference with regard
to survival probability. Profound im-
munodeﬁciency, late presentation, ad-
vanced CNS disease, and high rates of
comorbidity all conspire towards a dis-
mal prognosis. Prognosis in this setting
might be improved by earlier
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minimization of referral delays, and ac-
celerating diagnosis by using novel rapid
molecular assays, for example [23].
Careful screening and prophylaxis for
coinfections [24] is also important be-
cause multiple pathology appears to be
the rule rather than the exception in these
patients. More fundamentally, however,
these data highlight the need for effective
prevention of TB by using isoniazid
preventive therapy and ART as comple-
mentary strategies [25]. In addition, the
need for new effective drug treatments
for TB meningitis is abundantly clear.
The fact that the ﬁndings of Torok
et al [13] differ from those of other
strategy trials investigating the optimum
timing of ART during opportunistic in-
fections should come as no surprise.
Two other studies conducted in the
United States [26] and Zimbabwe [27],
for example, enrolled patients with acute
non-TB opportunistic infections and
cryptococcal meningitis, respectively,
and overall mortality risks differed
greatly (8.5% vs 64.8%). These cohorts
also had different rates of comorbidity
and standards of clinical care, and the
competing risks favoring either early or
deferred ART are likely to have differed
substantially between cohorts. In pa-
tients with cryptococcal meningitis
treated with oral ﬂuconazole therapy (a
fungistatic drug) in Zimbabwe, imme-
diate initiation of ART, compared with
initiation after 10 weeks, was associated
with a much higher mortality risk (88%
vs 54%) [27]. This suggests that, in the
absence of adequate fungicidal therapy,
early ART is harmful in this patient
group. In contrast, in North American
patients with non-TB acute opportu-
nistic infections, including patients with
cryptococcal meningitis who receive
amphotericin, early ART was associated
with a halving of the risk of progression
to AIDS and death [26].
Careful comparison of differences in
the outcomes of ART strategy trials in-
volving patients with TB may yield
further important insights. The Cam-
bodian Early versus Late Introduction of
Antiretrovirals (CAMELIA) trial studied
a cohort of patients with very advanced
immunodeﬁciency (median CD41 cell
count, 25 cells/lL) and pulmonary and/
or extrapulmonary TB but involved only
1 patient with a diagnosis of TB men-
ingitis [10]. This compared a similar
ART initiation strategy (ART within 2
weeks of treatment vs ART within 2
months) to that used by Torok et al [13].
Overall mortality in the CAMELIA study
was much lower than that observed by
Torok et al [13] (22.5% vs 57.7%), and
mortality was 34% lower in the early
ART initiation arm than it was in the
deferred arm. What was intriguing was
that this important mortality beneﬁt
accrued with increasing duration of
follow-up, being most marked during
the second year after randomization
[10]. The mechanism underlying this
delayed survival beneﬁt is not clear and
was not related to differences in immu-
nological or virological response to ART.
However, any potential long-term ac-
crual of survival beneﬁt would be un-
likely to be seen in the cohort studied by
Torok et al [13], because the high early
mortality occurred very early during
follow-up.
In summary, although several strategy
trials examining the optimum timing
of ART during opportunistic infections
have found that early ART is beneﬁcial
[10, 11, 26], the exceptions are those
studies involving patients with severe
CNS infections in resource-limited set-
tings [13, 27]. Thus, the question of
the optimum timing clearly has more
than one right answer [7]. The timing
of ART is just one component of
a complex package of care that must
include optimum treatment for the
opportunistic infection in question, op-
timum treatment of other comorbidities,
and optimized prevention of new
opportunistic infections. In the case of
TB meningitis in Vietnam, the stark
reality may be that the prognosis of
the patients is so poor that adjustments
in the timing of ART are largely futile.
Thus, although efforts must be made
towards earlier diagnosis and optimized
delivery of the current standard of care,
new solutions are desperately needed.
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